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Somatostatin in human pancreatic and gastric juice. PEPTIDES 2: Suppl. 2, 271-274, 1981 .-----Considerable amounts of IRS 
are secreted after secretin injection in human pancreatic juice collected during endoscopic retrograde cholangiopancreatog- 
raphy. The mean IRS levels in the pancreatic juice of non-diabetic patients were 79_ + 10 (SE) pedml. The IRS levels in 
NIDDM were considerably higher, the mean value being 1635_+ 313 (SE) pg/mi. The mean IRS level in IDDM were 312 _+ 15 l 
(SE) pg/ml. In IDDM, those patients whose blood glucose levels were well controlled by insulin showed low pancreatic 
juice IRS ranging from non-detectable to 46 pg/ml. On the other hand, those with uncontrolled hyperglycemia showed IRS 
levels ranging from 452 to 1047 pg/ml. Gel-filtration profiles of IRS in pancreatic juice extracts were not consistent in all 
cases. Some showed IRS peaks eluting with SS14 and SS28, while others contained IRS species that were eluted in more 
retarded fractions. The retarded IRS fraction exhibited biological activity indistinguishable from that of SS14 as indexed 
using a quantitative cytochemical method. 
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SOMATOSTATIN is found in a variety of  organs, and ad- 
ministration of  this peptide induces a variety of  actions. Fur- 
thermore, the stimuli or secretagogues which evoke 
somatostatin release from these various organs are not 
necessarily the same. While one substance may stimulate 
somatostatin release from one organ, it may also inhibit se- 
cretion from another [3]. These findings suggest that 
somatostatin may be a local hormone regulated by specific 
stimuli more or less unique to the respective organ. Regard- 
less of  whether or not somatostatin is secreted in a paracrine 
or endocrine manner via local portal  circulation, its action 
appears to be confined to the vicinity of  its site of  secretion. 
Somatostatin is also released into the gastric and intestinal 
lumen in animals [11]. However ,  there are few studies of the 
intraluminal secretion of  somatostatin in humans. Recently 
we demonstrated the presence of a high concentration of  
immunoreactive somatostatin (IRS) in human pancreatic 
juice [6]. The concentration was considerably higher in pan- 
creatic juice from patients with non-insulin dependent  dia- 
betes mellitus (NIDDM) than non-diabetic patients. In one 
patient with insulin dependent  diabetes melhtus (IDDM), the 
concentration was lower than that of  all of  the non-diabetic 
patients. However ,  whether a low concentration of  IRS is a 
general feature of  IDDM is unclear. The present study was 
conducted to further examine this problem and to obtain 
information on the chemical characteristics of  IRS in pan- 
creatic juice. This paper  also reports a preliminary study on 
somatostatin in human gastric juice. 
METHOD 
Fifteen subjects without pancreatic and biliary diseases, 
and 5 NIDDM patients and 7 IDDM patients were studied. 
Pancreatic juice was collected during endoscopic retrograde 
cholangiopancreatography (ERCP) by the method described 
by Kawanishi et al. [8]. All subjects were sedated with IV 
meperidine (50-100 mg) and/or diazepan (5-10 rag). To 
facilitate cannulation, the patients also received IV atropine 
(0.4-0.6 mg) and/or glucagon (1-3 U) (Eli Lilly and Co.) to 
obtain adequate relaxation of  the duodenum and the sphinc- 
ter of  Oddi. The cannula was introduced at least 5 mm into 
the pancreatic duct and secured. When a successful cannu- 
lation was achieved, secretin (1 U/kg) was given as a single 
IV bolus injection. Boots secretin (Warren Teed Lab. ,  USA) 
was given to 15 patients, and Karolinska secretin (GHRU, 
Karolinska Institute) were given to 12 patients. Pancreatic juice 
was collected under gentle negative pressure with a 10 ml 
syringe. Two to three ml of  pancreatic juice initially collected 
were discarded and the secretion collected over the subsequent 
15 min was utilized for somatostatin assay. After collecting 
pancreatic juice, a contrast material (-Renografm) was injected. 
Pancreatograms were obtained in all 27 patients. Specimens 
were immediately mixed with aprotinin, 500 KIU/ml, 
(Trasylol, FBA Pharmaceuticals,  Germany) in ice-chilled 
tubes and stored at -60°C until assayed. To one ml of pan- 
creatic juice was added 0.1 ml concentrated acetic acid/con- 
centrated formic acid ( l / l )  and then 4 ml acetone. The sam- 
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pies were then vortexed and centrifuged at 2000 rpm for 15 
min at 4°C. The supernatant was decanted into a tube coated 
with 0.1% gelatin and 1 ml water was added to dilute the 
acetone, followed by 6 ml of organic solvent (ethyl ace- 
tate/ether=3/1). Samples were then mixed, and centrifuged 
at 2000 rpm for 5 min. After the upper (organic) layer was 
aspirated off the aqueous phase was dried at 40-45°C under 
N~ gas. The extraction procedure used eliminates nearly all 
proteins including enzymes, lipids, and pigments, and there- 
fore minimizes possible interferences in RIA with these 
substances. The dried residue was dissolved in RIA diluent 
and aliquots were assayed for somatostatin. 
Some extracts of the pancreatic juice which contained a 
high concentration of or extracts of pooled pancreatic juice 
from non-diabetic patients IRS were chromatographed on a 
Sephadex G-25 (fine) column using 1 M acetic acid contain- 
ing 0.05-0.1% gelatin as eluant. All fractions were 
lyophilized, dissolved in RIA diluent or water, and assayed 
for somatostatin by RIA. The bioactivity of some of the 
fractions was also determined by measuring their ability to 
stimulate carbonic anhydrase activity in guinea pig stomach 
oxyntic cells using quantitative cytochemistry. A linear log 
dose-response was obtained between 2.9x10 -14 M to 
2.9×10 -11 M in this method [10]. 
RIA was performed as described elsewhere using a rabbit 
anti-somatostatin serum R101 [1]. In some assays, antiserum 
R207 was also used. The recognition sites of R101 are di- 
rected towards positions 5 to 13 of the somatostatin 14 
(SS 14) molecule, including the rind portion, whereas R207 is 
directed towards the N-terminal amino acids. Both elonga- 
tion and deletion of the N-terminal amino acids results in a 
loss of binding activity with antiserum R207. Antiserum 
R101 and R207 were used at final dilutions of 1:21,000 and 
1:7,000 respectively, nSI-N-Tyr-SS and nSI-TyrH-SS were 
used as the radioligands for RIA with antiserum R101 and 
R207, respectively. 
Gastric juice was collected from 6 non-diabetic and one 
NIDDM patient after overnight fasting. The gastric tube was 
inserted so that its end was located at the proximal portion of 
the antrum. After the residual content was aspirated, gastric 
juice was collected by continuous gentle aspiration for 4 con- 
secutive 15 min periods. Then, pentagastrin (0.6 ~g/rng) or 
secretin (2 U/kg) was administered IV as a bolus injection. 
Gastric juice was collected for 4 additional 15 rain periods. 
Specimens were immediately placed in ice-chilled tubes con- 
taining Pepstatin A (100 /zg/ml) an inhibitor of the 
enzyme pepsin, which may degrade somatostatin at low pH. 
After mixing, gastric juice was then neutralized with 0.1 N 
NaOH and placed in boiling water for 10 min. The specimens 
were then cooled and stored at -600C until assayed. Boiled 
gastric juice was determined for somatostatin by RIA with- 
out extraction. Bound and free hormone were separated by a 
double antibody method. The mean recoveries of 100 pg and 
500 pg/ml of added somatostatin were 78 and 96%, respec- 
tively. 
RESULTS AND DISCUSSION 
In non-diabetic patients, pancreatic juice immunoreactive 
somatostatin (IRS), in terms of SS14, ranged from 43 to 201 
pg/ml, averaging 79__. 10 (SE) pg/ml. These values were con- 
siderably greater than the IRS values in the peripheral 
plasma processed by a similar method. These plasma IRS 
levels were less than 20 pg/ml during fasting [1]. There were 
no significant differences in pancreatic juice IRS levels 
TABLE 1 
IRS (PG/ML) IN HUMAN PANCREATIC JUICE EXTRACTS FROM 
NON-DIABETICS, NIDDM AND IDDM 
Non-Diabetics (15) NIDDM (5) IDDM (7) 
Mean 79 1635 312 
_+SDM 38 700 400 
_+SEM 10 313 151 
Range 43-201 843-2287 0- ! 047 
associated with age or sex of the patients. Glucagon or at- 
ropine, which were administered before ERCP, did not seem 
to affect IRS levels. Thus, IRS levels in non-diabetic patients 
were found within a fairly narrow range after administration 
of various doses of these drugs, or without receiving either of 
them (Table 1). 
Surprisingly, IRS levels in NIDDM were 10-30 times 
greater than those in non-diabetic patients. On the other 
hand, IRS levels in IDDM varied considerably (Table 1). 
Four out of seven IDDM showed low IRS values ranging 
from non-detectable to 46 pg/ml, whereas the remaining 3 
patients showed high IRS levels ranging from 452 to 1047 
pg/ml. It is interesting that IDDM patients with low IRS were 
well controlled by insulin, whereas those with high IRS 
levels were poorly or only moderately controlled. On the 
other hand, all of the patients with NIDDM were well con- 
trolled by an appropriate diet or small doses of insulin. 
Therefore, it is unlikely that the levels of IRS in the pancre- 
atic juice were directly related to the levels of blood glucose. 
However, a fundamental difference in exocrine IRS secre- 
tion appears to be present between NIDDM and IDDM. Al- 
though exocrine IRS secretion clearly increases in al  
NIDDM and uncontrolled IDDM, and decreases in con- 
trolled IDDM, it is still not certain if this change parallels the 
endocrine secretion of pancreatic somatostatin. 
It was necessary to administer secretin or glucagon to 
obtain sufficient amounts of pancreatic juice. Since both se- 
cretin and glucagon are known to stimulate endocrine IRS 
release, the IRS values obtained in this study may not repre- 
sent the basal exocrine secretion of somatostatin. It is 
possible that the differences in the IRS levels between non- 
diabetics and NIDDM, and those between non-diabetics and 
controlled IDDM, are due to hyper-responsivity to the se- 
cretagogue in NIDDM and hyposensitivity in the controlled 
IDDM. Although the glucagnn and Boots secrefin prepara- 
tions are slightly contaminated with somatostatin (4 pg/U 
and 7 pg/100 U, respectively), it is unlikely that the IRS in the 
pancreatic juice originates from this contamination. This 
suggestion is strengthened by the observation that similar 
IRS levels were obtained after injection of Karolinska se- 
cretin, which is devoid of somatostatin. However, our results 
stand in contrast to those of Conlon et al. [5] who found that 
dog pancreatic juice was devoid of IRS during secretin stimu- 
lation. 
In ob/ob or db/db diabetic mice, which are considered to 
resemble NIDDM in humans, pancreatic and gastric 
somatostatin contents are lower than those of non-diabetic 
control animals [4]. On the other hand, in streptozotocin- 
induced diabetic rats, which may resemble IDDM, the con- 
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FIG. 1. Gel filtration profile of immunoreactive somatostatin (IRS) 
in human pancreatic juice extracts, obtained from non-diabetic 
(pooled) and one NIDDM patients. Immunoreactive somatostatin 
(IRS) from the fractions were determined by RIA using Anti SS 
#101. Rf (latter peak)=0.48, Rf (earlier peak)=0.61. The column 
parameters are shown in the figure. 
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FIG. 2. Ion exchange chromatography of somatostatin 28, SS 28 
(upper panel), and big immunoreactive somatostatin, big IRS, (lower 
panel) in human pancreatic juice extract. IRS from the fractions 
were determined by RIA using Anti SS #101. As shown in the lower 
panel, fractions 21-22 from Fig. 1 were subjected to ion exchange 
chromatography on CM-Sephadex C-25. 
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FIG. 3. Gel filtration of  human pancreatic juice extract from an 
NIDDM patient other than the one in Fig. 1. IRS from the fractions 
were determined by RIA using Anti SS # 101. Rf (latter peak)=0.40, 
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FIG. 4. Somatostatin activity measured hy a quantitative cytochem- 
ical method. Fr. 44 from the pancreatic juice extract, represented in 
Fig. 3, was examined for biological activity using quantitative 
cytochemistry in the guinea pig stomach oxyntic cell system. Dose 
response curves of SSI4 and fraction 44 are shown. 
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tent of  somatostatin in the pancreas and the stomach is ele- 
vated. Plasma IRS levels are also elevated in streptozotocin- 
induced diabetic rats [2]. Therefore, we expected that if any 
differences in pancreatic juice IRS were found, they would 
rise in IDDM and decrease in NIDDM. This, however,  was 
not the case. 
The route through which pancreatic somatostatin is se- 
creted into the pancreatic juice remains to be clarified. Fujita 
et al. [7] reported an insulo-acinar system which could carry 
islet somatostatin. Endocrine cells found throughout the 
non-islet portion could also be a source of IRS in exocrine 
pancreatic secretion [9]. 
Gel-filtration of  pancreatic juice extracts from non- 
diabetics (pooled) and one NIDDM patient yielded similar 
IRS profiles (Fig. 1). In both case two IRS peaks were found. 
The latter peak (Rf=0.48) was considerably larger than the 
earlier peak (Rf=0.61). The latter peak also coeluted with 
SS 14 whereas the earlier peak coeluted with SS28. Both this 
early peak and the retarded peak were detected by antiserum 
R101 which requires integrated ring structure necessary for 
biological activity. When the earlier peak was subjected to 
ion exchange on CM-Sephadex C-25, two IRS peaks were 
eluted, one eluting with SS28 and the other eluting in earlier 
fractions (Fig. 2). Whether the IRS species eluting with SS28 
indeed represents SS28 requires further chemical identifica- 
tion. 
Gel-filtration of  pancreatic juice extract from an NIDDM 
patient also showed 2 IRS peaks,  but both peaks were eluted 
in fractions more retarded than those containing SS14 (Fig. 
3). The earlier fraction was examined for biological activity 
using quantitative cytochemistry in the guinea pig stomach 
oxynic cell system by Shapiro et al. [10]. The dose response 
curve of this fraction was superimposable on that obtained 
with SS14 in the range between 10 -11 and 10 -14 M of  the 
extract in terms of SS14 in RIA (Fig. 4). Although we have 
not completed examining all IRS peaks on gel-filtration, it is 
likely that the IRS in pancreatic juice detected by antiserum 
R101 is biologically active. 
In contrast  to pancreatic juice,  the IRS levels in most 
gastric juice specimens were undetectable or very low before 
and after stimulation with pentagastrin or secretin, except  in 
one case of  NIDDM. The possibility that the low values were 
due to degradation of somatostatin by enzymes during col- 
lection cannot be excluded. However ,  in one patient with 
NIDDM, gastric juice IRS levels rose considerably during 
the second and third collections after pentagastrin stimula- 
tion (21.3 ng/ml and 30.5 ng/ml, respectively). Whether this 
is a general response in NIDDM awaits further investigation. 
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